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Background: This study aimed to investigate the expression profile of cyclooxygenase-2 (COX-2) in desmoid tumor
specimens and to evaluate the correlation of intratumoral COX-2 expression with pain status.
Methods: Sixteen patients with histologically proven desmoid tumors who attended our institution between 2003
and 2010 were enrolled in this study. COX-2 protein expression in desmoid tumors was determined by
immunohistochemistry. COX-2 - positive cells had similar morphology to that of mast cells, and therefore,
immunohistochemical staining for tryptase was performed in co-localized sections. The number of COX-2 -positive
cells in 10 consecutive fields was counted at 400× magnification. Patients were stratified into 2 groups according to
the number of COX-2- positive cells, the COX-2 -positive group (≧10 COX-2 -positive cells) and the COX-2 -negative
group (<10 COX-2 -positive cells). The prevalence of painful tumors was compared between the 2 groups.
Results: COX-2 was expressed in 9 patients (56%). COX-2 proteins were expressed not in tumor cells but in
tryptase-positive mast cells in the stroma of desmoid tumors. 6 of 9 patients in COX-2 -positive group had painful
tumors. This difference was statistically significant according to the chi-squared test (p = 0 .036), suggesting a
positive correlation between COX-2 expression and tumor-associated pain.
Conclusions: Our results indicated that COX-2 secretion from mast cells modulates desmoid tumor-associated
pain. In addition, mast cells may at least in part contribute to the pathogenesis of desmoid tumors.
Virtual slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1490389349103056.
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Desmoid tumors are rare clonal fibroblastic prolifera-
tions that arise in the extremities, girdles, chest, abdom-
inal wall, and neck. They are characterized by infiltrative
growth and a high risk of local recurrence even after
complete surgical excision [1]. Several reports have sug-
gested a link between cyclooxygenase-2 (COX-2) expres-
sion and the proliferation of desmoid tumors [2,3].
These findings provide clinical evidence for the use of
COX-2 inhibitors in the treatment of desmoid tumors.
Most patients present with an asymptomatic, firm,
poorly circumscribed mass, but some complain of severe
tumor-associated pain. These painful masses often cause* Correspondence: emrmkt@yahoo.co.jp
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reproduction in any medium, provided the ordecreased joint mobility and functional impairment. COX-
2 converts arachidonic acid into prostaglandins, the major
modulator of pain. In this study, the hypothesis that COX-
2 regulates desmoid tumor-associated pain was examined
by immunohistochemical evaluation of COX-2 expression
in tumor samples. The relationship between intratumoral
COX-2 expression and pain status was evaluated.
Materials and methods
For the use of these clinical materials for research pur-
poses, prior consent from the patients and approval
from the Institutional Review Board of Sapporo Medical
University Hospital was obtained.
Subjects
The study included 16 patients who were treated and
followed up at our hospital between April 2003 andtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Details of the clinical features
Case Age (yrs) Sex Location Pain Duration of
symptoms (Month)
Clinical characteristics COX-2 expression Treatment
1 28 F Thoracic wall (back) - - - - WR
2 35 F Anterior chest wall + 5 Spontaneous pain, pressure pain + WS
3 16 F Thigh + 12 Pressure pain + WR
4 46 M Thoracic wall (back) - - - - RB
5 33 F Thoracic wall (back) - - - + WR
6 52 F Knee - - - - WS
7 80 M Abdominal wall + 3 Pressure pain + WS
8 37 F Abdominal wall - - - + WR
9 66 F Thoracic wall (back) - - - - WS
10 33 F Arm + 1 Spontaneous pain, pressure pain + RB
11 14 F Calf + 7 Pressure pain + WS
12 67 F Axilla + 1 Spontaneous pain, pressure pain + WS
13 50 F Thoracic wall (back) - - - - WS
14 25 F Thigh - - - - WS
15 27 F Thoracic wall + 1 Pressure pain - WS
16 55 F Thoracic wall - - - + WS
M; male, F; female, WR; wide resection; WS, watch and see; RB; resection biopsy.
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formed to confirm the diagnosis of desmoid tumor.
Clinical details and follow-up information were ob-
tained by reviewing the patients’ medical charts. All
information on tumor-related pain was recorded at
presentation.
Immunohistochemical analysis
COX-2 protein expression in desmoid tumors was deter-
mined by immunohistochemistry. Immunohistochemical
analysis was performed using the labeled streptavidin-
biotin method and tissue sections from paraffin
blocks. Immunophenotyping for COX-2 and tryptaseFigure 1 Immunohistochemistry demonstrated no positive staining w
and eosin and (b) COX-2).was performed using monoclonal mouse primary anti-
bodies for COX-2 (BD Biosciences, San Jose, CA;
1:500) and tryptase (Dako Corp., Glostrup, Denmark;
1:200). Mast cells were identified by tryptase staining.
Several previously characterized chondrosarcoma samples
were used as positive controls. The immunohistochemical
results were evaluated by a pathologist (MT) who was
blinded to the patient’s clinical status. The number of
COX-2 positive cells in 10 consecutive fields was counted
at 400× magnification. The patients were stratified into 2
groups according to the number of COX-2 -positive cells,
the COX-2 positive group (≧10 COX-2 -positive cells) and
the COX-2 negative group (<10 COX-2 -positive cells)ith COX-2 protein within the tumor cells (X100, (a) Hematoxylin
Figure 2 Tryptase clearly co-expressed in the COX-2 positive cells (X100, (a) COX-2 and (b) tryptase).
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The chi-squared test was used to examine the correlation
between COX-2 expression in desmoid tumors and pain.
Statistical significance was defined as p < 0.05. Data were




Details of the clinical features are reported in Table 1.
The patients were 2 men and 14 women, 16–80 years of
age (median, 36 years). The tumors were located in the
back (n = 5), abdominal wall (n = 2), leg (n = 3) [thigh, 2;
lower leg, 1], arm (n = 1), axilla (n = 1), and anterior
chest wall (n = 1). Treatment procedures consisted were
wide resection (n = 4), resection biopsy (n = 2), and sim-
ple observation (n = 10). Seven patients (case 2, 3, 7, 10,
11, 12, and 15) complained of tumor pain.
Immunohistochemical analysis
Immunohistochemistry demonstrated no positive stain-
ing for the COX-2 protein within the tumor cells of all
samples from the 16 patients (Figure 1). In contrast, sev-
eral small, round COX-2 -positive cells were detected
within the tumoral stroma (Figure 1). COX-2 -positive
cells were similar in morphology to mast cells. There-
fore, we performed immunohistochemical staining for
tryptase in co-localized sections. As shown in Figure 2,
tryptase staining was seemed coincided in the COX-2
-positive cells, suggesting that COX-2 proteins were
expressed in tryptase-positive mast cells inside the des-
moid tumors, and not in the tumor cells themselves. SixTable 2 COX-2 expression and tumor-related pain
Painful Painless
COX-2 -positive group 6 3
COX-2 -negative group 1 6
p = 0 .036out of 7 patients in the COX-2 -negative group had
painless tumors. In contrast, 6 out of 9 patients in COX-
2- positive group had painful tumors. This difference
was statistically significant as assessed by the chi-squared
test (Table 2, p = 0.036), suggesting a positive correlation
between COX-2 expression and tumor-associated pain.
Discussion
Mast cells are mobile cells derived from bone marrow
that circulate in the blood. Mature mast cells are scat-
tered throughout tissues, including connective tissue [4].
The role of mast cells in connective tissue is still a mat-
ter of speculation, and it has been suggested that these
cells participate in cell regulation and control of the ac-
cumulation of connective tissue components. Several re-
ports indicate that mast cells are potentially fibrogenic,
since they secrete potent mediators of fibrosis [5,6]. One
of the main components of the secretory granules of
mast cells is tryptase [7], an enzyme found exclusively in
these cells. Tryptase is involved in diverse biological ac-
tivities such as fibrogenesis and stimulation of fibroblast
proliferation [8,9]. These findings suggest that mast cells
are involved in the pathogenesis of desmoid tumors
through the action of tryptase, a mast cell-derived prote-
ase. Recent studies have shown that tryptase induces
COX-2 expression by the specific cleavage of protease-
activated receptor-2 [10,11]. COX-2 expression is signifi-
cantly elevated in several neoplasms, including desmoids
tumor [2,3]. COX-2 overexpression leads to increased
prostaglandin E2 production, which in turn promotes
the growth of desmoid tumors. Furthermore, treatment
with COX-2 inhibitors induces the shrinkage of desmoid
tumors.
Recent reports have demonstrated that desmoids tumor
cells express COX-2 protein [2,3]. However, we failed to
show the expression of COX-2 protein within the tumor
cells. Conversely, COX-2 -positive mast cells were identi-
fied within the desmoid tumors. In addition, a positive
correlation between COX-2 expression and tumor-related
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mast cells, not tumor cells, may modulate desmoid tumor-
related pain. In addition, there could be connection be-
tween mast cells, at least in part, and the pathogenesis
of desmoids tumors.
In conclusion, these results suggest a link between
clinical symptoms and the tumor microenvironment in
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